Penumbra (PEN) Margin Expansion To 11.8% Tests Bulls High P E Narrative

Penumbra (PEN) has put fresh numbers on the table for Q1 2026, reporting revenue of US$374.8 million and basic EPS of US$0.83, anchored by trailing 12 month revenue of about US$1.5 billion and EPS of US$4.37 that follow a period of very large year over year earnings growth. The company has seen quarterly revenue move from US$324.1 million and EPS of US$1.02 in Q1 2025 to US$374.8 million and EPS of US$0.83 in Q1 2026. Over the same period, trailing 12 month revenue has moved from US$1.2 billion and EPS of US$1.09 at the start of 2025 to about US$1.5 billion and US$4.37 respectively. This sets up a results season in which investors are likely to focus closely on how the stronger profit margins feed into the story.

See our full analysis for Penumbra.

With the headline figures in place, the next step is to line these results up against the most common narratives around Penumbra to see which stories are supported by the data and which ones are challenged by it.

See what the community is saying about Penumbra

Margins Step Up To 11.8% On Trailing Basis

• Over the last 12 months, Penumbra converted US$1.5b of revenue into US$171.0 million of net income, which works out to an 11.8% net margin compared with 3.4% a year earlier.
• Bulls point out that this margin profile lines up with the idea of a business moving toward higher earnings power. The latest quarter shows some friction, as Q1 2026 net income of US$32.6 million on US$374.8 million of revenue sits below the trailing 12 month averages, which means:
  • Bullish expectations around margin expansion are supported by the trailing jump in net margin, yet the step down from Q4 2025 net income of US$47.3 million highlights that the path can be uneven from one period to the next.
  • Consensus narrative calls out new product launches and mix shifting to higher margin therapies, and the trailing margin improvement is consistent with that story. The quarter to quarter wobble shows why bulls are still watching execution closely rather than assuming a straight line.

Penumbra's margin trend is central to the optimistic case that stronger profitability can support the business over time, and the trailing 12 month data gives you a clearer view of that story beyond a single quarter. 🐂 Penumbra Bull Case

Sharp EPS Ramp Meets A Rich P/E Of 74.6x

• EPS over the last 12 months came in at US$4.37 compared with US$1.09 a year earlier, and with the stock at US$324.65 that translates into a trailing P/E of 74.6x, well above peer and industry averages of 26.1x and 23.9x.
• Bears argue that even with earnings growing very strongly over the past year and forecasts calling for about 19.3% annual EPS growth, the current multiple embeds a lot of success already, especially when:
  • Revenue is forecast to grow about 11.5% per year, only slightly ahead of the 11.4% US market benchmark, so bears see the 74.6x P/E as a big premium to pay for a growth rate that is not vastly different from the broader market.
  • The share price of US$324.65 also sits above the DCF fair value estimate of US$204.07, which critics see as another sign that valuation is stretched even after factoring in the recent 305% earnings growth.

For a beginner investor, the key trade off here is that strong EPS momentum is set against a very high earnings multiple, which is exactly what the cautious narrative focuses on. 🐻 Penumbra Bear Case

Quarterly Revenue Trend Backs Growth Story, With Some Softness In Profit

• Looking at the last six reported quarters, revenue has moved from US$315.5 million in Q4 2024 to US$324.1 million in Q1 2025 and up to US$374.8 million in Q1 2026, while basic EPS across the same stretch has ranged from US$0.88 to US$1.21 and now US$0.83.
• Consensus narrative leans on new clinical data and product launches to support ongoing growth in large treatment areas, and the revenue run from US$1.2b to US$1.5b on a trailing 12 month basis fits that view. Yet the Q1 2026 EPS of US$0.83 versus Q4 2025 EPS of US$1.21 shows:
  • The top line is moving higher over time, which lines up with expectations that new therapies and expanded sales coverage are adding volume and mix benefits.
  • The recent dip in quarterly EPS versus the prior three quarters reminds you that even when the longer term growth trend looks supportive, shorter term swings in costs and margins are still very much part of the story.

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Penumbra on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

Does this mix of strong numbers and differing narratives feel optimistic or cautious to you? Take a closer look at the details and move quickly to shape your own view by checking the 2 key rewards

See What Else Is Out There

Penumbra pairs a very high 74.6x P/E and a share price above a DCF fair value estimate with quarterly profit that currently trails its recent EPS peak.

If that mix of rich valuation and uneven earnings makes you uneasy, consider shifting some attention to companies screened as 51 high quality undervalued stocks and see which ideas look more reasonably priced right now.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com